These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

161 related articles for article (PubMed ID: 17916042)

  • 1. The future of cell therapies in the treatment of Parkinson's disease.
    Laguna Goya R; Kuan WL; Barker RA
    Expert Opin Biol Ther; 2007 Oct; 7(10):1487-98. PubMed ID: 17916042
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Graft-induced dyskinesias fail to respond to 5HT1A agonist in the long-term.
    Beaulieu-Boire I; Fasano A
    Mov Disord; 2015 May; 30(6):872-3. PubMed ID: 25758209
    [No Abstract]   [Full Text] [Related]  

  • 3. Cellular replacement therapy for Parkinson's disease--where we are today?
    Redmond DE
    Neuroscientist; 2002 Oct; 8(5):457-88. PubMed ID: 12374430
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Graft-induced dyskinesias in Parkinson's disease: what is it all about?
    Barker RA; Kuan WL
    Cell Stem Cell; 2010 Aug; 7(2):148-9. PubMed ID: 20682443
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Graft placement and uneven pattern of reinnervation in the striatum is important for development of graft-induced dyskinesia.
    Carlsson T; Winkler C; Lundblad M; Cenci MA; Björklund A; Kirik D
    Neurobiol Dis; 2006 Mar; 21(3):657-68. PubMed ID: 16256359
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Update on fetal transplantation: the Swedish experience.
    Lindvall O
    Mov Disord; 1998; 13 Suppl 1():83-7. PubMed ID: 9613723
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Focal not widespread grafts induce novel dyskinetic behavior in parkinsonian rats.
    Maries E; Kordower JH; Chu Y; Collier TJ; Sortwell CE; Olaru E; Shannon K; Steece-Collier K
    Neurobiol Dis; 2006 Jan; 21(1):165-80. PubMed ID: 16095907
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Can human fetal cortical brain tissue transplant (up to 20 weeks) sustain its metabolic and oxygen requirements in a heterotopic site outside the brain? A study of 12 volunteers with Parkinson's disease.
    Bhattacharya N; Chhetri MK; Mukherjee KL; Ghosh AB; Samanta BK; Mitra R; Bhattacharya M; Bhattacharya S; Bandopadhyaya T
    Clin Exp Obstet Gynecol; 2002; 29(4):259-66. PubMed ID: 12635741
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Fatal cyst formation after fetal mesencephalic allograft transplant for Parkinson's disease.
    Mamelak AN; Eggerding FA; Oh DS; Wilson E; Davis RL; Spitzer R; Hay JA; Caton WL
    J Neurosurg; 1998 Oct; 89(4):592-8. PubMed ID: 9761053
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Transplantation of embryonic porcine mesencephalic tissue in patients with PD.
    Schumacher JM; Ellias SA; Palmer EP; Kott HS; Dinsmore J; Dempsey PK; Fischman AJ; Thomas C; Feldman RG; Kassissieh S; Raineri R; Manhart C; Penney D; Fink JS; Isacson O
    Neurology; 2000 Mar; 54(5):1042-50. PubMed ID: 10720272
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Ontogenesis of embryonic porcine ventral mesencephalon in the perspective of its potential use as a xenograft in Parkinson's disease.
    Molenaar GJ; Hogenesch RI; Sprengers ME; Staal MJ
    J Comp Neurol; 1997 May; 382(1):19-28. PubMed ID: 9136809
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Dyskinesias after transplantation in Parkinson's disease.
    Piccini P
    Lancet Neurol; 2002 Dec; 1(8):472. PubMed ID: 12849327
    [No Abstract]   [Full Text] [Related]  

  • 13. CNS immunological modulation of neural graft rejection and survival.
    Borlongan CV; Stahl CE; Cameron DF; Saporta S; Freeman TB; Cahill DW; Sanberg PR
    Neurol Res; 1996 Aug; 18(4):297-304. PubMed ID: 8875445
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Stem cell transplantation: a promising therapy for Parkinson's disease.
    Wang Y; Chen S; Yang D; Le WD
    J Neuroimmune Pharmacol; 2007 Sep; 2(3):243-50. PubMed ID: 18040857
    [TBL] [Abstract][Full Text] [Related]  

  • 15. How to improve the survival of the fetal ventral mesencephalic cell transplanted in Parkinson's disease?
    Liu J; Huang HY
    Neurosci Bull; 2007 Nov; 23(6):377-82. PubMed ID: 18064069
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Dyskinesias following neural transplantation in Parkinson's disease.
    Hagell P; Piccini P; Björklund A; Brundin P; Rehncrona S; Widner H; Crabb L; Pavese N; Oertel WH; Quinn N; Brooks DJ; Lindvall O
    Nat Neurosci; 2002 Jul; 5(7):627-8. PubMed ID: 12042822
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Neuroscience. Fetal cells again?
    Holden C
    Science; 2009 Oct; 326(5951):358-9. PubMed ID: 19833936
    [No Abstract]   [Full Text] [Related]  

  • 18. Neural transplantation for the treatment of Parkinson's disease.
    Björklund A; Dunnett SB; Brundin P; Stoessl AJ; Freed CR; Breeze RE; Levivier M; Peschanski M; Studer L; Barker R
    Lancet Neurol; 2003 Jul; 2(7):437-45. PubMed ID: 12849125
    [No Abstract]   [Full Text] [Related]  

  • 19. Current status of clinical trials of neural transplantation in Parkinson's disease.
    Evans JR; Mason SL; Barker RA
    Prog Brain Res; 2012; 200():169-98. PubMed ID: 23195419
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Neural transplantation, trophic factors and Parkinson's disease.
    Kupsch A; Oertel WH
    Life Sci; 1994; 55(25-26):2083-95. PubMed ID: 7997067
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.